Avalyn Pharma: Funding, Investors & Team (Sep 2026)
Avalyn Pharma, headquartered in Seattle, Washington, is a biopharma company dedicated to progressing treatments for Idiopathic Pulmonary Fibrosis (IPF) and various other serious respiratory disorders. The company focuses on swiftly advancing AP01 as a therapy for IPF, offering further potential treatments for IPF through its pipeline, enhancing the management and results of severe respiratory diseases, and creating innovative inhaled therapeutics. Founded in 2011, Avalyn Pharma is committed to advancing respiratory health.
Avalyn Pharma has raised $275M across 2 funding rounds on record, the most recent a Series D of $100M announced in Jul 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Avalyn Pharma Company Profile and Key Stats
Latest funding round on record: Jul 2025.
Avalyn Pharma Funding Rounds
Avalyn Pharma raised $175M in a Series C announced in Sep 2023.
1.8 years later, a Series D of $100M was announced in Jul 2025.
Avalyn Pharma Founders and Leadership Team
Contact details for the Avalyn Pharma team: 1 of 1 has an email address on file.
Start 14-day free trial →Avalyn Pharma Funding Compared to Other Biotechnology Startups
Avalyn Pharma's latest round of $100M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Avalyn Pharma in Biotechnology and Seattle
Companies Similar to Avalyn Pharma
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Avalyn Pharma Funding FAQs
What does Avalyn Pharma do?
Avalyn Pharma, headquartered in Seattle, Washington, is a biopharma company dedicated to progressing treatments for Idiopathic Pulmonary Fibrosis (IPF) and various other serious respiratory disorders. The company focuses on swiftly advancing AP01 as a therapy for IPF, offering further potential treatments for IPF through its pipeline, enhancing the management and results of severe respiratory diseases, and creating innovative inhaled therapeutics. Founded in 2011, Avalyn Pharma is committed to advancing respiratory health.
How much funding has Avalyn Pharma raised?
Avalyn Pharma has raised $275M across 2 rounds on record. The most recent is a Series D of $100M announced in Jul 2025.
When did Avalyn Pharma last raise funding?
Avalyn Pharma's most recent funding round on record is a Series D of $100M, announced in Jul 2025.
Who founded Avalyn Pharma?
FundedIQ lists Mark W Surber (Founder) at Avalyn Pharma.
Where is Avalyn Pharma headquartered?
Avalyn Pharma is based in Seattle, Washington, United States.
How many employees does Avalyn Pharma have?
Avalyn Pharma is in the 11-50 employee band.
How does Avalyn Pharma's funding compare to other Biotechnology startups?
Avalyn Pharma's latest round of $100M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Avalyn Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Avalyn Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.